This article has Open Peer Review reports available.
Comparison of the efficacy of nafcillin and glycopeptides as definitive therapy for patients with methicillin-susceptible Staphylococcus aureus bacteremia: a retrospective cohort study
© The Author(s). 2018
Received: 2 May 2017
Accepted: 23 January 2018
Published: 30 January 2018
Studies have shown that the prognosis of the treatment of methicillin-susceptible S. aureus (MSSA) with glycopeptides is inferior compared to treatment with β-lactam. However, there are only few studies comparing treatment with antistaphylococcal penicillin alone to glycopeptide treatment. The aim of this study was to compare the efficacy of nafcillin, an antistaphylococcal penicillin, with that of glycopeptides as a definitive therapy for MSSA bacteremia.
Patients with MSSA bacteremia recruited from a tertiary referral hospital were enrolled in this retrospective cohort study. Demographic characteristics, laboratory data, and clinical outcome of the treatment were compared between a group receiving nafcillin and a group receiving glycopeptides.
A total of 188 patients with MSSA bacteremia were included in this study. The glycopeptide group had a higher rate of malignancy (28.6 vs. 60.8%, p < 0.001) and proportion of healthcare-associated infections (47.3 vs. 72.2%, p < 0.001) compared to the nafcillin group. The ratio of skin and soft tissue infections (30.0 vs. 16.7%, p = 0.037) and bone and joint infections (17.8 vs. 6.3%, p = 0.022), as well as levels of C-reactive protein (139.60 vs. 107.61 mg/dL, p = 0.022) were higher in the nafcillin group. All-cause 28-day mortality was significantly high in the glycopeptide group (7.7 vs. 20.6%, p = 0.013).
In patients with MSSA bacteremia, all-cause 28-day mortality rate was higher in a group treated with glycopeptides than in a group treated with nafcillin. Therefore, the use of nafcillin should be considered as a definitive therapy for MSSA bacteremia.
Staphylococcus aureus (S. aureus) is one of the most common causes of community-acquired and healthcare-associated bacteremia . The incidence of infection induced by methicillin-resistant S. aureus (MRSA) has been increasing [2, 3]. In Korea, a recent nationwide survey reported a methicillin-resistance rate of S. aureus of 66% in the general population . Therefore, many clinicians therefore use glycopeptides such as vancomycin as their first choice of antibiotics for empirical treatment of S. aureus bacteremia to cover both MRSA and methicillin-susceptible S. aureus (MSSA) before confirming antibiotic susceptibility. However, some physicians continue to use the glycopeptide without changing to β-lactam antibiotics after confirmation of MSSA bacteremia.
Many studies comparing the efficacy of β-lactam antibiotics, including antistaphylococcal penicillin and glycopeptides, as empirical therapy for MSSA bacteremia have been conducted, and β-lactam agents have been found to be superior in the treatment of MSSA bacteremia compared with glycopeptides in these studies [5–8]. Wong et al. reported that empiric β-lactams was associated with earlier clearance of MSSA bacteremia compared to vancomycin (70.7 vs. 97.1 h, p = 0.007) . Additionally, Schweizer et al. reported that β-lactams showed protective effectiveness against mortality compared to vancomycin in patients with MSSA bacteremia (adjusted hazard ratio, 0.21; 95% CI, 0.09–0.47) . However, there were few studies comparing glycopeptides and antistaphylococcal penicillin such as nafcillin alone as a treatment for MSSA bacteremia. This study aimed to compare the efficacy of nafcillin, an antistaphylococcal antibiotic, with that of glycopeptides including vancomycin and teicoplanin, as definitive therapy for patients with MSSA bacteremia.
We consecutively included patients with confirmed S. aureus bacteremia recruited from a single tertiary referral hospital from April 2012 to June 2016 in this retrospective cohort study. The referral hospital is a 2400-bed institution affiliated with Yonsei University College of Medicine in Seoul, South Korea. All participants were aged 18 years or older. Patients receiving a definitive therapy with nafcillin, vancomycin, or teicoplanin were included in this study. Patients who had MRSA infections or received treatment with other single antibiotics such as first generation cephalosporin, quinolone, or β-lactam/β-lactamase inhibitor combinations were excluded. Patients with bacteremia caused by other pathogens and those who died before the causative organism could be confirmed were also excluded. Participants were divided into the “nafcillin group” and the “glycopeptide group”. The study was approved by the institutional review board of the Yonsei University Health System Clinical Trial Center (#4–2017-0070).
Baseline characteristics such as age, sex, and preexisting comorbidities including cardiovascular disease, cerebral vascular accidents, dementia, lung disease, autoimmune disease, peptic ulcer disease, chronic kidney disease, diabetes, liver disease, and malignancy were recorded. Data on the source of the bacteremia and on whether the patient’s infection was community-acquired or healthcare-associated were collected. According to the source of bacteremia, we subdivided the patient sample into groups with catheter-related infection, pneumonia, urinary tract infection, skin and soft tissue infection, bone and joint infection, intra-abdominal infection, and primary bacteremia.
Laboratory tests were undertaken within the first 24 h after a culture was drawn. Tests included white blood cell (WBC) count, platelet counts, creatinine levels, estimated glomerular filtration rate, total bilirubin levels, prothrombin time (international normalized ratio), and C-reactive protein (CRP) levels. As the index of disease severity, the Pitt bacteremia score was calculated . To assess the clinical outcome, we analyzed the patient data with respect to hospitalization duration, whether or not participants received intensive care unit (ICU) care, duration of stay at the ICU, persistent bacteremia, and all-cause 28-day mortality. The results of an antimicrobial susceptibility test, performed in accordance with the Clinical & Laboratory Standards Institute guidelines, were obtained from the patients’ medical records .
If bacteremia was identified within 48 h of admission and the participant had no history of admission to healthcare institutions within 3 months prior to admission, their infection was assumed to be community-acquired. If bacteremia was identified after 48 h or if the participant had an admission history within 3 months prior to admission, their infection was assumed to be healthcare-associated. Definitive therapy was defined as initiated or continued antibiotic treatment after identification of the pathogen in blood culture and in an antibiotic susceptibility test . The source of infection, such as catheter-related infection, pneumonia, urinary tract infection, skin and soft tissue infection, bone and joint infection, and intra-abdominal infection was defined based on the criteria laid out by the Centers for Disease Control and Prevention, USA . WBC counts equal to or above 10,000/mm3 are considered leukocytosis. Leukopenia is defined as WBC counts under 4000/mm3. Thrombocytopenia is defined as platelet counts less than 150 × 103/mm3. Persistent bacteremia is defined as the isolation of S. aureus in blood cultures obtained from peripheral veins for more than 7 consecutive days despite adequate antibiotic administration for more than 5 days. Mortality involving at least one of the following are defined as bacteremia-related mortality: (i) blood cultures were positive at the time of death; (ii) death occurred before the resolution of bacteremia; (iii) death occurred during hospitalization without other specific cause except bacteremia .
Continuous variables were expressed as mean ± standard deviation or median (interquartile range) and compared using the Student’s t-test if the variables followed a normal distribution. Continuous variables with skewed distribution were compared using the Mann-Whitney U-test. The chi-squared test was used when all the categorical variables included in the analysis were 5 or more. If any of the categorical variables included in the analysis has a value of less than 5, it was analyzed using Fisher’s exact test. To compare survival rates between the nafcillin group and the glycopeptide group, a Kaplan-Meier survival curve was used. The Cox regression model was used to analyze prognostic factors for mortality. All statistical analyses were performed using the Statistical Package for the Social Sciences 18.0 software (SPSS Inc., Chicago, IL, USA). P values under 0.05 were considered statistically significant.
Comparison of baseline characteristics and laboratory test results between the patient groups treated with either nafcillin or glycopeptides
(n = 188)
(n = 91)
(n = 97)
Age, years, mean ± SD
62.37 ± 15.14
64.38 ± 14.53
60.46 ± 15.54
Underlying comorbidities, yes (%)
Cerebral vascular accident
Peptic ulcer disease
Chronic kidney disease
CA vs. HCA, HCA (%)
Pit bacteremia score, mean ± SD
1.56 ± 2.55
1.42 ± 2.39
1.69 ± 2.71
Infection focus, yes (%)
Urinary tract infection
Skin and Soft tissue infection
Bone and Joint infection
WBC, /mm3, median (IQR)
Leukocytosis or Leukopenia, yes (%)
Platelet counts, ×103/mm3, median (IQR)
Thrombocytopenia, yes (%)
eGFR, mL/min/mm3, mean ± SD
62.88 ± 28.60
62.38 ± 28.27
63.35 ± 29.06
Total bilirubin, mg/dL, median (IQR)
Prothrombin time (INR), median (IQR)
CRP, mg/dL, median (IQR)
With regard to the antimicrobial susceptibility of identified MSSA, we found a relatively high resistance rate to penicillin G (85.1%), erythromycin (17.1%), and clindamycin (15.4%). Resistance to other antibiotics was relatively low. There was no significant difference in resistance rates between the two patient groups except for clindamycin (8.8 vs. 21.6%, p = 0.016) (Additional file 1).
Clinical outcome of the different treatments
(n = 188)
(n = 91)
(n = 97)
Hospitalization period, days, median (IQR)
ICU stay, days, mean ± SD
5.03 ± 14.10
3.71 ± 12.47
6.26 ± 15.44
Persistent bacteremia, (%)
All-cause 28-day mortality, yes (%)
S. aureus bacteremia is a very severe clinical condition that clinicians often experience. Since the infection rate caused by MRSA is increasing, many clinicians use the glycopeptide empirically. However, despite of confirming MSSA bacteremia via bacterial culture, it is not uncommon to maintain glycopeptide as definitive therapy for the reason that severe comorbidities and disease severity. There have been many studies related to the choice of a definitive therapeutic agent for MSSA bacteremia, but no study had compared prognosis with glycopeptide with nafcillin alone, an antistaphylococcal agent. In our current study, we found that the 28-day mortality rate was significantly lower in a group of patients with MSSA bacteremia receiving definitive therapy with nafcillin compared to a group receiving treatment with. This finding suggests that nafcillin should be considered as the first choice for definitive antimicrobial therapy in MSSA bacteremia.
Our finding of higher mortality in the vancomycin group is in accordance with findings from several recent studies. Mcdanel et al. reported a higher mortality rate in patients who received vancomycin monotherapy compared with patients who received β-lactam monotherapy, as definitive therapy for MSSA bacteremia, after adjustment for confounding factors such as severity of illness, comorbidities, age, and others . Kim et al. reported higher mortality in patients who were treated with vancomycin for MSSA bacteremia compared with patients receiving β-lactam agents .
Some explanations for the relative inferiority of vancomycin in the treatment of MSSA have been proposed . Generally, β-lactam agents are classified as bactericidal to MSSA, whereas the bactericidal effect of vancomycin is lower than that of β-lactam agents [15, 16]. Furthermore, vancomycin has a relatively narrow therapeutic range as compared to β-lactam agents, pharmacologically . Additionally, because teicoplanin is a bacteriostatic agent with similar efficacy as vancomycin, teicoplanin also poses problems that is smilar with vancomycin in the treatment of MSSA .
In this study, the prevalence of malignancy and the proportion of healthcare-associated infections were higher in the glycopeptide group than in the nafcillin group. In addition, skin and soft tissue infection as well as bone and joint infection were more common in the nafcillin group than in the glycopeptide group. However, the use of glycopeptides was found to be the significant prognostic factor for mortality when adjusting for these variables. Thus, despite several confounding variables, the choice of antibiotics, in this case nafcillin versus glycopeptides, in the treatment of MSSA bacteremia is an important factor affecting patient mortality.
On the other hand, we found no significant difference in persistent bacteremia in this study. Kim et al. reported that there was no statistical difference in eradication of infection foci between a β-lactam treatment group and a vancomycin treatment group in patients with MSSA bacteremia . However, Wong el al. reported a significant difference in the frequency of prolonged bacteremia between a β-lactam treatment group and a vancomycin treatment group . Furthermore, Park et al. reported significant differences in bacteremia duration between a β-lactam treatment group, a vancomycin treatment group, and a combination treatment group .
This study has several limitations. First, this is a retrospective cohort study and it is thus subject to selection bias. Second, all data were collected from a single center, so that generalization of these results to other institutions might be questionable. Additional prospective studies with more selective and larger populations involving multiple centers are necessary.
In conclusion, we find that all-cause 28-day mortality in MSSA bacteremia is higher in patients receiving glycopeptides as definitive therapy compared to patients receiving nafcillin. Therefore, the use of nafcillin should be a first choice for definitive antimicrobial treatment in MSSA bacteremia.
The authors thank to the medical staffs in the department of Infectious disease and department of laboratory medicine of Yonsei University College of Medicine.
This work was supported by the National Research Foundation of Korea(NRF) grant funded by the Korea government(MSIT) (2017R1C1B5017875). This study was supported by a faculty research grant of Yonsei University College of Medicine (6–2017- 0054)
Availability of data and materials
All data generated or analyzed during this study are included in this published article and its Additional files.
Conception and design of study: DHO and NSK. Acquisition of data: JJK, JK, HS, SJL, YCK, EJK, IYJ and WYJ. Data analysis and interpretation: DHO and NSK. Drafting of manuscript and critical revision: SJJ, SHH, JYC, YGS, JMK and NSK. Approval of final version of manusciript: DHO, JJK, JK, HS, SJL, YCK, EJK, IYJ, WYJ, SJJ, NSK, SHH, JYC, YGS, and JMK.
Ethics approval and consent to participate
The study was approved by the institutional review board of the Yonsei University Health System Clinical Trial Center (#4–2017-0070). The informed consent was waived because this study was a retrospective study with review of related data through the electronic medical record.
Consent for publication
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- van Hal SJ, Jensen SO, Vaska VL, Espedido BA, Paterson DL, Gosbell IB. Predictors of mortality in Staphylococcus Aureus bacteremia. Clin Microbiol Rev. 2012;25(2):362–86.View ArticlePubMedPubMed CentralGoogle Scholar
- National Nosocomial Infections Surveillance S. National nosocomial infections surveillance (NNIS) system report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control. 2004;32(8):470–85.View ArticleGoogle Scholar
- Klevens RM, Morrison MA, Nadle J, Petit S, Gershman K, Ray S, Harrison LH, Lynfield R, Dumyati G, Townes JM, et al. Invasive methicillin-resistant Staphylococcus Aureus infections in the united states. JAMA. 2007;298(15):1763–71.View ArticlePubMedGoogle Scholar
- Yong D, Shin HB, Kim YK, Cho J, Lee WG, Ha GY, Choi TY, Jeong SH, Lee K, Chong Y, et al. Increase in the prevalence of Carbapenem-resistant Acinetobacter isolates and ampicillin-resistant non-Typhoidal salmonella species in Korea: a KONSAR study conducted in 2011. Infect Chemother. 2014;46(2):84–93.View ArticlePubMedPubMed CentralGoogle Scholar
- Wong D, Wong T, Romney M, Leung V. Comparative effectiveness of beta-lactam versus vancomycin empiric therapy in patients with methicillin-susceptible Staphylococcus Aureus (MSSA) bacteremia. Ann Clin Microbiol Antimicrob. 2016;15:27.View ArticlePubMedPubMed CentralGoogle Scholar
- Kim SH, Kim KH, Kim HB, Kim NJ, Kim EC, Oh MD, Choe KW. Outcome of vancomycin treatment in patients with methicillin-susceptible Staphylococcus Aureus bacteremia. Antimicrob Agents Chemother. 2008;52(1):192–7.View ArticlePubMedGoogle Scholar
- McDanel JS, Perencevich EN, Diekema DJ, Herwaldt LA, Smith TC, Chrischilles EA, Dawson JD, Jiang L, Goto M, Schweizer ML. Comparative effectiveness of beta-lactams versus vancomycin for treatment of methicillin-susceptible Staphylococcus Aureus bloodstream infections among 122 hospitals. Clin Infect Dis. 2015;61(3):361–7.View ArticlePubMedGoogle Scholar
- Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus Aureus infections in adults and children: executive summary. Clin Infect Dis. 2011;52(3):285–92.View ArticlePubMedGoogle Scholar
- Schweizer ML, Furuno JP, Harris AD, Johnson JK, Shardell MD, McGregor JC, Thom KA, Cosgrove SE, Sakoulas G, Perencevich EN. Comparative effectiveness of nafcillin or cefazolin versus vancomycin in methicillin-susceptible Staphylococcus Aureus bacteremia. BMC Infect Dis. 2011;11:279.View ArticlePubMedPubMed CentralGoogle Scholar
- Hill PC, Birch M, Chambers S, Drinkovic D, Ellis-Pegler RB, Everts R, Murdoch D, Pottumarthy S, Roberts SA, Swager C, et al. Prospective study of 424 cases of Staphylococcus Aureus bacteraemia: determination of factors affecting incidence and mortality. Intern Med J. 2001;31(2):97–103.View ArticlePubMedGoogle Scholar
- Performance standards for antimicrobial disk susceptibility tests. In., standard-tenth edn. Wayne, Pennsylvania: Clinical and Laboratory Standards Institution; 2009: M02-A09.Google Scholar
- Rasmussen JB, Knudsen JD, Arpi M, Schonheyder HC, Benfield T, Ostergaard C. Relative efficacy of cefuroxime versus dicloxacillin as definitive antimicrobial therapy in methicillin-susceptible Staphylococcus Aureus bacteraemia: a propensity-score adjusted retrospective cohort study. J Antimicrob Chemother. 2014;69(2):506–14.View ArticlePubMedGoogle Scholar
- Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control. 2008;36(5):309–32.View ArticlePubMedGoogle Scholar
- Sterling SA, Puskarich MA, Glass AF, Guirgis F, Jones AE. The impact of the Sepsis-3 septic shock definition on previously defined septic shock patients. Crit Care Med. 2017;Google Scholar
- Stevens DL. The role of vancomycin in the treatment paradigm. Clin Infect Dis. 2006;42(Suppl 1):S51–7.View ArticlePubMedGoogle Scholar
- Jones RN. Microbiological features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains. Clin Infect Dis. 2006;42(Suppl 1):S13–24.View ArticlePubMedGoogle Scholar
- Wood MJ. The comparative efficacy and safety of teicoplanin and vancomycin. J Antimicrob Chemother. 1996;37(2):209–22.View ArticlePubMedGoogle Scholar
- Park GE, Ko JH, Cho SY, Ha YE, Lee NY, Kang CI, Chung DR, Song JH, Peck KR. Empirical combination of a beta-lactam to vancomycin may not improve outcomes of methicillin-susceptible Staphylococcus Aureus bacteremia, compared to vancomycin monotherapy. Eur J Clin Microbiol Infect Dis. 2017;Google Scholar